Home > Journals > Minerva Pediatrics > Past Issues > Minerva Pediatrica 2010 February;62(1) > Minerva Pediatrica 2010 February;62(1):71-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Pediatrica 2010 February;62(1):71-8

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Pediatric antifungal therapy. Part II: neonatal infections

Allen U., Richardson S., McGuire W., Bow E., Robinson J., Rotstein C., Doyle J., Davies D., Hui C., Le Saux N., Merchant P., Laverdiere M., Read S.

Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada


PDF


The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.

top of page